Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 10,724 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hematologic Disease Clear all

Conditions: Hematologic Neoplasms
Interventions: Stem cell transplantation, Fludarabine, Cyclophosphamide, Etoposide, Doxorubicin, Vincristine, Prednisone, Methotrexate, Cyclosporine, Apheresis; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Interventions: Gamunex-C, 10% Injectable Solution; Drug
Lead sponsor: Grifols Biologicals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: St. Petersburg, Florida • Fort Wayne, Indiana • Westbrook, Maine + 2 more

Conditions: Twin Twin Transfusion Syndrome
Interventions: Selective Laser Photocoagulation of Communicating Vessels; Device
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Chronic Lymphocytic Leukemia (CLL)
Interventions: Obinutuzumab, Venetoclax, Fludarabine, Cyclophosphamide, Rituximab, Bendamustine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 4
States / cities: Aurora, Colorado • Bethesda, Maryland • Knoxville, Tennessee + 1 more

Conditions: Refractory Multiple Myeloma
Interventions: plerixafor, filgrastim; Drug · Biological
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 19 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Primary Immunodeficiency, Agammaglobulinemia, Hypogammaglobulinemia, Antibody Deficiency
Interventions: Kedrion IVIG 10%; Biological
Lead sponsor: Kedrion S.p.A.; Industry
Eligibility: 2 Years to 70 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 12
States / cities: Little Rock, Arkansas • North Palm Beach, Florida • Atlanta, Georgia + 8 more

Conditions: Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Acute Lymphoblastic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, t(9;22)
Interventions: Dexamethasone, Ponatinib Hydrochloride, Rituximab, Venetoclax; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Interventions: Data Capture, Electronic Medical Record; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor, Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor, Hemophilia A
Interventions: Emicizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Not listed
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 5
States / cities: Los Angeles, California • Atlanta, Georgia • Indianapolis, Indiana + 2 more

Conditions: Sickle Cell Disease
Interventions: Amani; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Interventions: decitabine; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: B-cell Adult Acute Lymphoblastic Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia, Untreated Adult Acute Lymphoblastic Leukemia
Interventions: nilotinib, rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, methotrexate, cytarabine, prednisone, mesna, dexamethasone, leucovorin calcium; Drug · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Conditions: Multiple Myeloma
Interventions: Pomalidomide, Dexamethasone, Aspirin; Drug
Lead sponsor: Celgene Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 14
States / cities: Scottsdale, Arizona • Denver, Colorado • Tampa, Florida + 10 more

Conditions: Monoclonal Gammopathy of Undetermined Significance
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: 30 Years and older
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hypereosinophilic Syndrome
Interventions: Mepolizumab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 6
States / cities: La Jolla, California • New Haven, Connecticut • Rochester, Minnesota + 3 more

Conditions: Smoldering Plasma Cell Myeloma
Interventions: Daratumumab, Dexamethasone, Lenalidomide, Quality-of-Life Assessment, Questionnaire Administration; Biological · Drug · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 742
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 490 more

Conditions: Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Lymphomatoid Granulomatosis, Leukemia-Lymphoma, Adult T-Cell
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1,295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Fanconi Anemia
Interventions: CD34+ selected cells; Biological
Lead sponsor: Neena Kapoor, M.D.; Other
Eligibility: 8 Weeks to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Multiple Myeloma
Interventions: bb2121; Biological
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 9
States / cities: Stanford, California • Bethesda, Maryland • Boston, Massachusetts + 4 more

Conditions: Myeloid Leukemia
Interventions: AVE9633; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Asthma
Interventions: Mepolizumab, SOC; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 339 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 16
States / cities: Newport Beach, California • Riverside, California • Rolling Hills Estates, California + 13 more

Conditions: Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndromes (MDS), Myeloproliferative Disorder, Non-Hodgkin's Lymphoma
Interventions: Conditioning Chemotherapy, Cord blood graft; Drug · Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Non Hematologic Cancers, Metastatic Cancer, Lymphoma
Interventions: VS-5584; Drug
Lead sponsor: Verastem, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 4
States / cities: Scottsdale, Arizona • Los Angeles, California • New York, New York + 1 more

Conditions: Anemia of Prematurity (AOP)
Interventions: Restrictive transfusions based on SCOR assessment, Liberal transfusions; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: Up to 3 Days
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: New York, New York

Search by objective public record fields.

Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers

A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma

Selective Laser Photocoagulation of Communicating Vessels in Twin-Twin Transfusion Syndrome

A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide

Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)

Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

Outcomes After Chimeric Antigen Receptor Therapy and Radiation Therapy for Hematologic Malignancies

A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors

Feasibility and Acceptability of Amani

Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia

MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma

Observation of the Incidence and Natural History of MGUS in Patients Undergoing Weight Reduction Surgery

A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Tissue Collection for Studies of Lymph Cancer

Unrelated HSCT in Patients With Fanconi Anemia

Study of bb2121 in Multiple Myeloma

Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia

A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects

Cord Blood Transplant in Adults With Blood Cancers

Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma

Combining Restrictive Guidelines and a NIRS SCORE to Decrease RBC Transfusions